Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

Eli Lilly (LLY) shares rallied 14.3% in the last trading session to close at $839.96. ... Merck's consensus EPS estimate for the upcoming report has changed -4% over the past month to $2.16.

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Though specifics of the order were not clear, shares of all large drugmakers, J&J, Eli Lilly, Pfizer, Merck, Gilead, Bristol-Myers, Amgen and several other U.S. pharmaceutical stocks were on the ...

A cautious culture cost Novo its obesity lead. Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly.

Eli Lilly stock is up 6.6% today and 50% for the year. Driving those gains is excitement over two potential blockbusters—one for obesity and diabetes and another for Alzheimer’s.

(Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Merck & Company. The company’s shares closed yesterday at $81.37. Don’t Miss TipRanks ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.